Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma VEGF levels after intravitreal aflibercept in exudative AMD
2014-000103-27Phase 2Completed
- Start
- Aug 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of aflibercept in age-related macular degeneration (AMD). Primary endpoint: Plasma VEGF levels after aflibercept treatment. Started Aug 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2014-000103-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000103-27.